Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus

Journal of the American Osteopathic Association

Volumn 112, Issue 1 SUPPL. 1, 2012, Pages

  Freeman, Jeffrey S ^a  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

BLOOD; DRUG EFFECT; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME;

EID: 84856787506     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. http://www.cdc.gov/diabetes/pubs /pdf/ndfs_2011.pdf. Accessed November 22, 2011.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with typ. diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lance. 1999; 354(9178):602]. Lancet. 1998;352(9131):837-853.
3. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291(3):335-342.
4. Dodd AH, Colby MS, Boye KS, Fahlman C, Kim S, Briefel RR. Treatment approach and HbA1c control among US adults with typ. diabetes: NHANES 1999-2004. Curr Med Res Opin. 2009;25(7):1605-1613.
5. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle [review]. Biomed Biotechno. 2010;2010:476279.
6. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologi. 2004;47(1):31-39.
7. DeFronzo RA. From the triumvirate to the ominous octet. new paradigm for the treatment of typ. diabetes mellitus [Banting Lecture]. Diabete. 2009;58 (4):773-795.
8. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Car. 2010;34 (suppl 1):S11-S61.
9. La Barre J. Sur les possibilities d'un traitement du diabète par l'incrétine. Bull Aca. Med Belg. 1932;12:620-634.
10. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. Clin Endocrinol Meta. 1964;24:1076-1082.
11. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of typ. diabetes. Diabete. 2004;53(suppl 3):S190-S196.
12. Deacon CF. Therapeutic strategies based on glucagon-like peptid. [review]. Diabete. 2004;53 (9):2181-2189.
13. Dunning BE, Foley JE, Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1 [published online ahead of print August 13, 2005]. Diabetologi. 2005;48(9):1700-1713.
14. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinolog. 2002;143 (11):4397-4408.
15. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptid. receptor are mediated through both glucagon-like peptid. receptor-dependent and-independent pathways [published online ahead of print April 21, 2008]. Circulatio. 2008;117 (18):2340-2350.
16. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice [published online ahead of print January 16, 2009]. Diabete. 2009;58(4):975-983.
17. Rachman J, Barrow BA, Levy JC, Turner RC. Nearnormalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologi. 1997;40 (2):205-211.
18. Byetta. Exenatide injection [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc; 2010.
19. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with typ. diabetes. Diabetes Car. 2004;27(11):2628-2635.
20. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with typ. diabetes [published online ahead of print February 9, 2011]. Clin Endocrinol Meta. 2011;96(5):1301-1310.
21. Victoza. Liraglutide (rDNA origin) injection [package insert]. Princeton, NJ: Novo Nordisk A/S; 2011.
22. Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for typ. diabetes (LEAD-3 Mono). randomised, 52-week, phase III, double-blind, paralleltreatment trial [published online ahead of print September 24, 2008]. Lance. 2009;373(9662):473-481.
23. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M; Albiglutide Study Group. Potential of albiglutide. long-acting GLP-1 receptor agonist, in typ. diabetes. randomized controlled trial exploring weekly, biweekly, and monthly dosing [published online ahead of print July 10, 2009]. Diabetes Car. 2009;32(10):1880-1886.
24. Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators. Dose-dependent effects of the oncedaily GLP-1 receptor agonist lixisenatide in patients with Typ. diabetes inadequately controlled with metformin. randomized, double-blind, placebo-controlled trial. Diabet Me. 2010;27(9):1024-1032.
25. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of typ. diabetes [published online ahead of print March 16, 2005]. Diabetologi. 2005;48(4):616-620.
26. Januvia (sitagliptin) tablets [package insert]. Whitehouse Station, NJ: Merc. Co, Inc; 2011.
27. Brock CM. DPP-4 inhibitors: what is their place in therapy? US Pharmacis. 2010;35(5):8-13.
28. Tradjenta (linagliptin) tablets [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2011.
29. Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin. dipeptidyl peptidase-4 inhibitor in male typ. diabetes patients [published online ahead of print May 19, 2009]. Diabetes Obes Meta. 2009;11 (8):786-794.
30. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with typ. diabetes. Diabetes Car. 2006;29 (12):2632-2637.
31. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 021 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with typ. diabetes inadequately controlled with metformin alone. Diabetes Car. 2006;29(12):2638-2643.
32. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naive patients with typ. diabetes. Curr Med Res Opi. 2009;25 (10):2401-2411.
33. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with typ. diabetes. randomized, double-blind, placebo-controlled study. Diabetes Obes Meta. 2011;13(1):65-74. doi:10.1111/j.1463-1326.2010.01326.x.
34. Frederich R, Alexander JH, Fiedorek FT, et al. systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for typ. diabetes. Postgrad Me. 2010;122(3):16-27.
35. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with typ. diabetes. randomized, controlled trial [published online ahead of print December 6, 2010]. Ann Intern Me. 2011;154(2):103-112.
36. Ghosal S. Liraglutide in combination with insulin therapy for typ. diabetic patients: an early clinical experience data. Paper presented at: Annual Meeting of the American Diabetes Association; June 24-28, 2011; San Diego, CA.
37. Hollander P, Raslova K, Skjoth TV, Rastam J, Liutkus JF. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Meta. 2011;13(3):268-275. doi:10.1111/j.1463-1326.2010.01351.x.
38. Morrow L, Hompesch M, Guthrie H, Chang D, Chatterjee DJ. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Meta. 2011;13(1):75-80. doi:10.1111/j.1463-1326.2010.01322.x.
39. Raman VS, Mason KJ, Rodriguez LM, et al. The role of adjunctive exenatide therapy in pediatric typ. diabetes [published online ahead of print March 23, 2010]. Diabetes Car. 2010;33(6):1294-1296.
40. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment in typ. diabetes [published online ahead of print June 6, 2011]. Eu. Endocrino. 2011;165(1):77-84.
41. Astrup A, Rossner S, Van GL, et al; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity. randomised, double-blind, placebo-controlled study [published online ahead of print October 23, 2009]. Lance. 2009;374(9701):1606-1616.